SARomics Biostructures: An Advanced Technology Platform
Accelerating Discovery with Structural Insight!
SARomics Biostructures offers a cutting-edge services platform that leverages advanced methods and technologies developed over recent decades, supported by our team’s expertise. We have achieved significant success in this field, completing over 100 projects annually, which underscores the strong demand for our services. Our technology platform is fully equipped to manage all experimental steps required for successful structural biology and early drug discovery work. We utilize synchrotron radiation sources to obtain high-quality X-ray data, with our primary source being the local MAX IV synchrotron in Lund, located just a few kilometers from our laboratories. On average, we collect X-ray data at the BioMax beamline every 2 to 3 weeks. The video presentation below provides details of the BioMax beamline, which is equipped with state-of-the-art beamline technology.
To help our clients plan their work effectively, we offer additional detailed experimental information. Some of this information is presented in this section, while others are published as blog posts.
- Crystallographic fragment screening
- Practical aspects of BioNMR
- NMR spectroscopy in comparative higher order structure analysis
- Choosing a library for screening and initial hit identification
- Structure-based drug design strategies
- WAC™ fragment screening technology
For details of our services, please visit the corresponding pages:
X-ray crystallography services
NMR spectroscopy services
Fragment-based drug design services
Antibody structure & epitope mapping services
Please also visit our company blog for the latest news and additional details about our technology platform. You are welcome to contact us directly to discuss your project.
Designing a drug discovery strategy
SARomics Biostructures started as a company offering structural biology services, but over the years, it has expanded its platform to cover all aspects of structure-based drug design. The team has gained extensive experience in library screening, hit identification, and structure-based lead discovery. Based on our experience, we will discuss the main strategies for structure-based lead discovery and drug design. The choice of strategy depends on the available information, such as the three-dimensional structure of the drug target, known ligand structure (structures), and the availability of co-crystal structures of a ligand and target. Also, screening compound libraries and hit identification are crucial for any new lead discovery project.
In collaboration with our partner, RG Discovery, we operate an integrated drug discovery platform that leverages our proprietary weak-affinity chromatography (WAC™) fragment screening technology. The advantages of the WAC™ method are outlined on our integrated drug discovery services page. The following steps in the process, including fragment expansion and lead generation, are carried out by experienced medicinal chemists at RG Discovery in close collaboration with our computational chemistry, X-ray crystallography, and protein NMR spectroscopy teams. Our page about available structure-based drug design strategies provides more information.
In this five-minute video, Dr. Anna Gonzales takes us inside the BioMax experimental hutch to demonstrate how its amazing technology works: robotic crystal mounting and positioning the crystal in the X-ray beam, 460 samples for data collection that can be stored in liquid nitrogen, and brought into the beam as required, and the X-ray detector that allows an entire dataset to be collected within 40 seconds: this and much more. Don’t miss it!